MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that Chairman, Chief Executive Officer, and Co-Founder Dr. Shankar Musunuri will participate in two major investor conferences this September, highlighting the company’s strategy and clinical development programs.
Dr. Musunuri is scheduled for a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 5 p.m. ET in New York City. Later in the month, he will join a panel discussion titled “The FDA Gauntlet: Strategies for a Successful Run at Approval” at Biotech on Tap 2025 in Munich, Germany, on September 25 at 3:30 p.m. CET.
“Year after year, the H.C. Wainwright Global Investment Conference provides a great opportunity for us to meet with key investors in the biotech and healthcare space,” Musunuri said. “I look forward to broadening our reach into the European investment community during Biotech on Tap.”
Ocugen noted that members of its executive team will also hold one-on-one meetings with investors to discuss the company’s modifier gene therapy platform and business strategy. A live webcast of the New York session will be available on Ocugen’s investor site, with a replay accessible for 90 days.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.